Unique business model

About M1 Kliniken AG

M1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical field, the group offers products and services of the highest quality standards. Under the brand "M1 Med Beauty", beauty medical treatments are currently offered at more than 35 specialist centres. With six operating theatres and 35 beds, the M1 Schlossklinik für plastische und ästhetische Chirurgie in Berlin is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been driving forward its internationalisation and is currently also active in Austria, Switzerland, the Netherlands, England and Australia. In addition, the Group markets high-quality products under the brands "M1 Select" and "M1 Aesthetics" to private customers as well as doctors, pharmacies and wholesalers.


Strategy & goals

The strategic goal of the M1 Kliniken Group is to offer high quality medical services. Beauty products, beauty treatments and aesthetic surgeries are subject to high price sensitivity. The German Society for Consumer Research (GfK) has identified that the average market prices for breast surgery, liopsuction and wrinkle treatment are too expensive from the customer's point of view. The range of products and services offered by M1 Kliniken Group is therefore based on the price expectations of customers. By offering the highest quality at the best price, the demand for beauty treatments and aesthetic surgeries is increasing and new customer groups are being established.

Latest news

| Ad-hoc news

At today's balance sheet meeting, the Supervisory Board of M1 Kliniken AG (ISIN: DE000A0STSQ8) approved the annual financial statements and the consolidated financial statements of the Company for the 2025 financial year, as submitted by the Management Board, in accordance with §§ 171, 172 AktG. The annual financial statements are thereby adopted pursuant to § 172 AktG.

The Supervisory Board and the Management Board today resolved to propose to the Annual General Meeting a dividend of EUR 1.20 per dividend-bearing share.

The 2025 Annual Report of M1 Kliniken AG is expected to be published on 20 May 2026.

| Investor News

  • Group revenue: +7.4% to EUR 364.3 million (FY 2024: EUR 339.2 million)
  • EBITDA: +23.6% to EUR 39.4 million (FY 2024: EUR 31.9 million)
  • EBIT: +29.2% to EUR 34.6 million (FY 2024: EUR 26.8 million)
  • EBIT margin: 9.5% (FY 2024: 7.9%)
  • EBT: +29.5% to EUR 34.1 million (FY 2024: EUR 26.3 million)
  • Earnings per share: EUR 1.19 (FY 2024: EUR 0.85)

| Investor News

M1 Kliniken AG announces that the sale of HAEMATO Pharm GmbH by its majority holding, HAEMATO AG (85%), to the PHOENIX group was successfully completed effective as of the end of January 31, 2026.

| Investor News

The Supervisory Board of M1 Kliniken AG has appointed Ms. Katharina Zimmnau to the Executive Board of M1 Kliniken AG with effect from 10. December 2025.